A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-22. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
== Applications == Triethylamine is commonly employed in organic synthesis as a base. For example, it is commonly used as a base during the preparation of esters and amides from acyl chlorides. Such reactions lead to the production of hydrogen chloride which combines with triethylamine to form the salt triethylamine hydrochloride, commonly called triethylammonium chloride. (R, R' = alkyl, aryl):
O-linked glycopeptides recently have been shown to exhibit excellent CNS permeability and efficacy in multiple animal models with disease states. In addition one of the most intriguing aspects thereof is the capability of O-glycosylation to extend half life, decrease clearance, and improve PK/PD thereof the active peptide beyond increasing CNS penetration. The innate utilization of sugars as solubilizing moieties in Phase II and III metabolism (glucuronic acids) has remarkably allowed an evolutionary advantage in that mammalian enzymes are not directly evolved to degrade O glycosylated products on larger moieties. The peculiar nature of O-linked glycopeptides is that there are numerous examples which are CNS penetrant. The fundamental basis of this effect is thought to involve "membrane hopping" or "hop diffusion". The non-brownian motion driven "hop diffusion" process is thought to occur due to discontinuity of the plasma membrane. "Hop diffusion" notably combines free diffusion and intercomparmental transitions. Recent examples notably include high permeability of met-enkephalin analogs amongst other peptides. The full mOR agonist pentapeptide DAMGO is also CNS penetrant upon introduction of glycosylation.
== Use and effects == (R)-MDMA has a dose of 125 to 300 mg orally and a duration of 3.5 to 5.2 hours. It has been estimated that doses of 125 mg MDMA, 100 mg (S)-MDMA, and 300 mg (R)-MDMA are equivalent. The first modern clinical study of the comparative effects of MDMA, (R)-MDMA, and (S)-MDMA was published in August 2024. It compared 125 mg MDMA, 125 mg (S)-MDMA, 125 and 250 mg (R)-MDMA, and placebo. (R)-MDMA increased any drug effect, good drug effect, drug liking, stimulation, drug high, alteration of vision, and alteration of sense of time ratings similarly to MDMA and (S)-MDMA. However, (S)-MDMA 125 mg was more potent in increasing subjective effects, including stimulation, drug high, happy, and open, among others, than (R)-MDMA 125 or 250 mg or MDMA 125 mg. Ratings of bad drug effect and fear were minimal with MDMA, (R)-MDMA, and (S)-MDMA. In contrast to expectations, (R)-MDMA did not produce more psychedelic-like effects than (S)-MDMA. Besides subjective effects, (R)-MDMA increased heart rate, blood pressure, and body temperature similarly to MDMA and (S)-MDMA, though it was less potent in producing these effects. Body temperature was notably increased to the same extent with (R)-MDMA 250 mg as with MDMA 125 mg and (S)-MDMA 125 mg. The differences in effects between (R)-MDMA and (S)-MDMA may reflect the higher potency of (S)-MDMA rather than actual qualitative differences between the effects of (S)-MDMA and (R)-MDMA. It was estimated that equivalent effects would be expected with (S)-MDMA 100 mg, MDMA 125 mg, and (R)-MDMA 300 mg.
Sources: en.wikipedia.org
EC 1.1.99.9: pyridoxine 5-dehydrogenase EC 1.1.99.10: Now EC 1.1.5.9, glucose 1-dehydrogenase (FAD, quinone) EC 1.1.99.11: Now classified as EC 1.1.5.14, fructose 5-dehydrogenase EC 1.1.99.12: sorbose dehydrogenase EC 1.1.99.13: glucoside 3-dehydrogenase EC 1.1.99.14: glycolate dehydrogenase EC 1.1.99.15: Now EC 1.5.1.20, methylenetetrahydrofolate reductase [NAD(P)H] EC 1.1.99.16: Now EC EC 1.1.5.4, malate dehydrogenase (quinone) EC 1.1.99.17: Now EC 1.1.5.2, quinoprotein glucose dehydrogenase EC 1.1.99.18: cellobiose dehydrogenase (acceptor) EC 1.1.99.19: Now EC 1.17.99.4, uracil/thymine dehydrogenase EC 1.1.99.20: alkan-1-ol dehydrogenase (acceptor) EC 1.1.99.21: D-sorbitol dehydrogenase (acceptor) EC 1.1.99.22: glycerol dehydrogenase (acceptor) EC 1.1.99.23: Now EC 1.1.2.6, polyvinyl alcohol dehydrogenase (cytochrome) EC 1.1.99.24: hydroxyacid-oxoacid transhydrogenase EC 1.1.99.25: Now EC 1.1.5.8, quinate dehydrogenase (quinone), EC 1.1.99.26: 3-hydroxycyclohexanone dehydrogenase EC 1.1.99.27: (R)-pantolactone dehydrogenase (flavin) EC 1.1.99.28: glucose-fructose oxidoreductase EC 1.1.99.29: pyranose dehydrogenase (acceptor) EC 1.1.99.30: 2-oxoacid reductase EC 1.1.99.31: (S)-mandelate dehydrogenase EC 1.1.99.32: L-sorbose 1-dehydrogenase EC 1.1.99.33: Now EC 1.17.99.7, formate dehydrogenase (acceptor) EC 1.1.99.34: now EC 1.1.98.2, glucose-6-phosphate dehydrogenase (coenzyme-F420) EC 1.1.99.35: soluble quinoprotein glucose dehydrogenase EC 1.1.99.36: alcohol dehydrogenase (nicotinoprotein) EC 1.1.99.37: methanol dehydrogenase (nicotinoprotein) EC 1.1.99.38: 2-deoxy-scyllo-inosamine dehydrogenase (AdoMet-dependent) EC 1.1.99.39: D-2-hydroxyglutarate dehydrogenase EC 1.1.99.40: (R)-2-hydroxyglutarate—pyruvate transhydrogenase EC 1.1.99.41: 3-hydroxy-1,2-didehydro-2,3-dihydrotabersonine reductase EC 1.1.99.42: 4-pyridoxic acid dehydrogenase
Static self-assembly is significantly slower compared to dynamic self-assembly as it depends on the random chemical interactions between particles. Self assembly can be directed in two ways. The first is by manipulating the intrinsic properties which includes changing the directionality of interactions or changing particle shapes. The second is through external manipulation by applying and combining the effects of several kinds of fields to manipulate the building blocks into doing what is intended. To do so correctly, a high level of direction and control is required and developing a simple, efficient method to organize molecules and molecular clusters into precise, predetermined structures is crucial.
==== Toxicology in aquatic environments ==== The most environmentally relevant species of these nanoparticles are silver chloride within marine ecosystems and organic thiols within terrestrial ecosystems. Once Ag0 enters the environment, it is oxidized to Ag+. Of the potential species formed in seawater, such as Ag2S and Ag2CO3, AgCl is the most thermodynamically favored due to its stability, solubility, and the abundance of Cl− in seawater. Research has shown that partially oxidized nanoparticles may be more toxic than those that are freshly prepared. It was also found that Ag dissolutes more in solution when the pH is low and bleaching has occurred. This effect, coupled with ocean acidification and increasing coral reef bleaching events, leads to a compounding effect of Ag accumulation in the global marine ecosystem. These free formed Ag+ ions can accumulate and block the regulation of Na+ and Cl− ion exchange within the gills of fish, leading to blood acidosis which is fatal if left unchecked. Additionally, fish can accumulate Ag through their diet. Phytoplankton, which form the base level of aquatic food chains, can absorb and collect silver from their surroundings. As fish eat phytoplankton, the silver accumulates within their circulatory system, which has been shown to negatively impact embryonic fish, causing spinal cord deformities and cardiac arrhythmia. The other class of organisms heavily affected by silver nanoparticles is bivalves.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.